BioXcel Therapeutics, Inc. short interest in 2024
In 2024, BioXcel Therapeutics, Inc.'s disclosed short interest ran from 10.19% of shares outstanding on 12 Jan 2024 to 1.89% on 31 Dec 2024, a change of -8.30 percentage points. The year's high was 13.57% on 29 Feb 2024 and its low 0.81% on 31 Oct 2024, averaging 4.62% across 22 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 6.02 days on 12 Jan 2024. Full history: BioXcel Therapeutics, Inc..
Cite this page
By year: 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026
2024 in figures
- Start of year
- 10.19% (12 Jan 2024)
- End of year
- 1.89% (31 Dec 2024)
- Change
- -8.30 pp
- High
- 13.57% (29 Feb 2024)
- Low
- 0.81% (31 Oct 2024)
- Average
- 4.62%
- Highest days to cover
- 6.02 (12 Jan 2024)
Every report in 2024
| Settlement | Short interest | Days to cover | Filings since previous |
|---|---|---|---|
| 12 Jan 2024 | 10.19% | 6.02 | |
| 31 Jan 2024 | 8.39% | 5.21 | |
| 29 Feb 2024 | 13.57% | 2.53 | |
| 15 Mar 2024 | 10.72% | 3.91 | |
| 28 Mar 2024 | 8.15% | 4.86 | |
| 15 Apr 2024 | 6.83% | 4.98 | |
| 30 Apr 2024 | 4.91% | 3.68 | |
| 15 May 2024 | 5.33% | 3.24 | |
| 31 May 2024 | 4.85% | 2.30 | |
| 14 Jun 2024 | 4.87% | 2.97 | |
| 28 Jun 2024 | 5.30% | 1.58 | |
| 31 Jul 2024 | 1.98% | 1.31 | |
| 15 Aug 2024 | 1.79% | 1.25 | |
| 30 Aug 2024 | 1.67% | 1.83 | |
| 13 Sep 2024 | 1.71% | 1.73 | |
| 30 Sep 2024 | 1.27% | 1.00 | |
| 15 Oct 2024 | 1.41% | 1.55 | |
| 31 Oct 2024 | 0.81% | 1.00 | |
| 15 Nov 2024 | 1.46% | 1.25 | |
| 29 Nov 2024 | 2.10% | 1.11 | |
| 13 Dec 2024 | 2.47% | 1.24 | |
| 31 Dec 2024 | 1.89% | 1.00 |
See also: BioXcel Therapeutics, Inc.'s full history · most shorted US stocks of 2024 · today's US league.
About this data
US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.